David Olivares-Berjaga

Mr. David Olivares-Berjaga

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CMConstanza Morén
Constanza Morén
DODavid Olivares-Berjaga
David Olivares-Berjaga
AMAlbert Martínez-Pinteño
Albert Martínez-Pinteño
MBMiquel Bioque
Miquel Bioque
NFNatalia Rodriguez Ferret
Natalia Rodriguez Ferret
EPEduard Parellada
Eduard Parellada
Schizophrenia (SCZ) is a severe, chronic mental disorder of unknown etiology and limited therapeutic options. Bioenergetic deficits in the oxidative phosphorylation system (OXPHOS) during early postnatal brain development may underlie disrupted neuronal metabolism and synaptic signaling, contributing to the neurodevelopmental and behavioral disturbances observed in patients. This narrative review summarizes updated evidence linking mitochondrial-OXPHOS dysfunction to SCZ pathophysiology. The novelty lies in the focus on OXPHOS dysfunction at the enzymatic/functional level, rather than on genetic, transcriptional, or oxidative parameters. While complex I impairment has long been highlighted and proposed as a peripheral marker of the disease, recent studies also report alterations in other OXPHOS complexes and their precursors. These findings suggest that OXPHOS dysfunction is not isolated to a single enzymatic component but affects broader mitochondrial function, alongside oxidative stress, contributing to disease progression through mechanisms involving apoptosis, accelerated aging, and synaptic deterioration. OXPHOS dysfunction in both central and peripheral tissues further supports its relevance to SCZ. Overall, the literature points to mitochondrial OXPHOS abnormalities as a significant biological feature of SCZ. Whether these alterations are causal factors or consequences of disease processes remains unclear. Understanding OXPHOS dysregulation may open new avenues for targeted therapies.

14 January 2025 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
DODavid Olivares-Berjaga
David Olivares-Berjaga
AMAlbert Martínez-Pinteño
Albert Martínez-Pinteño
NFNatalia Rodriguez Ferret
Natalia Rodriguez Ferret
SMSergi Mas
Sergi Mas
CMConstanza Morén
Constanza Morén
PGPatricia Gasso
Patricia Gasso
Schizophrenia (SZ) is a deleterious brain disorder characterised by its heterogeneity and complex symptomatology consisting of positive, negative and cognitive deficits. Current antipsychotic drugs ameliorate the positive symptomatology, but are inefficient in treating the negative symptomatology and cognitive deficits. The neurodevelopmental glutamate hypothesis of SZ has opened new avenues in the development of drugs targeting the glutamatergic system. One of these new therapies involves the positive allosteric modulators (PAMs) of metabotropic glutamate receptors, mainly types 2/3 (mGluR2/3). mGluR2/3 PAMs are selective for the receptor, present high tolerability and can modulate the activity of the receptor for long periods. There is not much research in clinical trials regarding mGluR2/3 PAMs. However, several lines of evidence from animal models have indicated the efficiency of mGluR2/3 PAMs. In this review, focusing on in vivo animal studies, we will specifically discuss the utilization of SZ animal models and the various methods employed to assess animal behaviour before summarising the evidence obtained to date in the field of mGluR2/3 PAMs. By doing so, we aim to deepen our understanding of the underlying mechanisms and the potential efficiency of mGluR2/3 PAMs in treating SZ. Overall, mGluR2/3 PAMs have demonstrated efficiency in attenuating SZ-like behavioural and molecular deficits in animal models and could be useful for the early management of the disorder or to treat specific subsets of patients.

5 January 2024 in Psychiatry Research
Verified
Journal Article
Open access
LPLlucia Prohens
Llucia Prohens
NRNatalia Rodríguez
Natalia Rodríguez
ÀSÀlex-Gonzàlez Segura
Àlex-Gonzàlez Segura
AMAlbert Martínez-Pinteño
Albert Martínez-Pinteño
DODavid Olivares-Berjaga
David Olivares-Berjaga
SMSergi Mas
Sergi Mas
Genome-wide association studies (GWAS) have revealed the polygenic nature of treatment-resistant schizophrenia TRS. Gene expression imputation allowed the translation of GWAS results into regulatory mechanisms and the construction of gene expression (GReX) risk scores (GReX-RS). In the present study we computed GReX-RS from the largest GWAS of TRS to assess its association with clinical features. We perform transcriptome imputation in the largest GWAS of TRS to find GReX associated with TRS using brain tissues. Then, for each tissue, we constructed a GReX-RS of the identified genes in a sample of 254 genotyped first episode of psychosis (FEP) patients to test its association with clinical phenotypes, including clinical symptomatology, global functioning and cognitive performance. Our analysis provides evidence that the polygenic basis of TRS includes genetic variants that modulate the expression of certain genes in certain brain areas (substantia nigra, hippocampus, amygdala and frontal cortex), which at the same time are related to clinical features in FEP patients, mainly persistence of negative symptoms and cognitive alterations in sustained attention, which have also been suggested as clinical predictors of TRS. Our results provide a clinical explanation of the polygenic architecture of TRS and give more insight into the biological mechanisms underlying TRS.

1 February 2024 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Open access
DODavid Olivares-Berjaga
David Olivares-Berjaga
AMAlbert Martínez-Pinteño
Albert Martínez-Pinteño
NFNatalia Rodriguez Ferret
Natalia Rodriguez Ferret
SMSantiago Madero
Santiago Madero
LPLlucía Prohens
Llucía Prohens
PGPatricia Gasso
Patricia Gasso
Current treatment for schizophrenia (SZ) ameliorates the positive symptoms, but is inefficient in treating the negative and cognitive symptoms. The SZ glutamatergic dysfunction hypothesis has opened new avenues in the development of novel drugs targeting the glutamate storm, an inducer of progressive neuropathological changes. Positive allosteric modulators of metabotropic glutamate receptor 2 (mGluR2), such as JNJ-46356479 (JNJ), reduce the presynaptic release of glutamate, which has previously been demonstrated to attenuate glutamate- and dopamine-induced apoptosis in human neuroblastoma cell cultures. We hypothesised that JNJ treatment would modify the brain levels of apoptotic proteins in a mouse model of ketamine (KET)-induced schizophrenia. We analysed the levels of proapoptotic (caspase-3 and Bax) and antiapoptotic (Bcl-2) proteins by western blot in the prefrontal cortex and hippocampus of JNJ-treated mice. JNJ attenuated apoptosis in the brain by partially restoring the levels of the antiapoptotic Bcl-2 protein, which is significantly reduced in animals exposed to KET. Additionally, a significant inverse correlation was observed between proapoptotic protein levels and behavioural deficits in the mice. Our findings suggest that JNJ may attenuate brain apoptosis in vivo, as previously described in cell cultures, providing a link between neuropathological deficits and SZ symptomatology.

11 October 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
AMAlbert Martínez-Pinteño
Albert Martínez-Pinteño
DODavid Olivares-Berjaga
David Olivares-Berjaga
NFNatalia Rodriguez Ferret
Natalia Rodriguez Ferret
JMJuan-Ignacio Mena
Juan-Ignacio Mena
LPLucia Prohens
Lucia Prohens
PGPatricia Gasso
Patricia Gasso
Schizophrenia (SZ) is a complex mental disorder influenced by genetic, environmental, and neurobiological factors, with current treatments ineffective for negative symptoms and cognitive deficits. The glutamatergic hypothesis of SZ highlights the N-methyl-D-aspartic acid (NMDA) receptor dysfunction as a key factor, causing excitatory-inhibitory imbalance and synaptic inefficiency. Positive allosteric modulators (PAMs) of the metabotropic glutamate receptor 2 (mGluR2), such as JNJ-46356479 (JNJ), could be useful in treating these symptoms, especially when used in early stages of the disease. Previous results have shown that JNJ can reverse certain SZ-related behavioral and neuropathological deficits. This study evaluates, for the first time, the effects of early treatment with JNJ or clozapine (CLZ) in reversing molecular deficits related to glutamatergic and GABAergic pathways in mice postnataly exposed to ketamine (KET) on postnatal days (PND) 7, 9, and 11. Animals received JNJ or CLZ daily in the adolescent period (PND 35-60). Specifically, we investigated alterations in brain protein levels of VGLUT1, as a marker of glutamatergic synapses, and GAD65/67, as markers of GABAergic synapses. Changes in brain expression of 240 selected genes involved in glutamate and GABA pathways were also evaluated. Results demonstrated that postnatal KET exposure increased hippocampal VGLUT1 levels which were partially normalized after both pharmacological treatments, especially with JNJ. Additionally, we identified some genes that showed altered brain expression after drug treatment in our mouse model. In conclusion, this study provides evidence of SZ-related glutamate signaling alterations in adult mice postnatally exposed to KET, as well as of the effectiveness of JNJ in improving these alterations when administered during the early stages of the disease.

Verified
Journal Article
Open access
PDF file
Enric Rubio-ContrerasEnric Rubio-Contreras
Enric Rubio-Contreras
Nora CapellaNora Capella
Nora Capella
AMAlbert Martínez-Pinteño
Albert Martínez-Pinteño
DODavid Olivares-Berjaga
David Olivares-Berjaga
CMConstanza Morén
Constanza Morén
Schizophrenia (SCZ) is a complex psychiatric disorder with positive, negative, and cognitive symptoms that cause long-term functional impairment. Despite available treatments, limitations in addressing cognitive and negative symptoms, medication side effects, and poor adherence highlight the need for novel biomarkers to support precision medicine. Hair has emerged as a promising, non-invasive biological matrix for biomarker research. Hair analysis has been explored to detect trace elements, abused drugs, antipsychotics, cortisol, neurotransmitters, and to assess gene expression, with results often consistent with blood, urine, and post-mortem tissues. Its advantages include ease of sampling and the ability to provide long-term information, while limitations involve individual variability and methodological inconsistencies. This review summarizes current evidence on hair-based biomarkers in SCZ, critically evaluating their potential and challenges. By integrating molecular, metabolic, and genetic findings, we highlight the value of hair as a complementary tool for advancing biomarker discovery and personalized approaches in SCZ.